Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tiago Torres

Showing results (191-200 of 274) with videos related to

Pageof 28
Sort By:
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 13, 2025
Real-World Evidence on the Effectiveness and Safety of Spesolimab in the Treatment of Generalized Pustular Psoriasis Flares: A Case SeriesMartim Luz, M Ribeiro, M Alpalhão, et al.
Colloids and Surfaces. B, Biointerfaces|August 6, 2017
Topical co-delivery of methotrexate and etanercept using lipid nanoparticles: A targeted approach for psoriasis managementMara Ferreira, Luísa Barreiros, Marcela A Segundo, et al.
Dermatology and Therapy|October 23, 2025
Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic DermatitisMatthias Augustin, April Armstrong, Naiem T Issa, et al.
Dermatology and Therapy|June 26, 2026
A Response to: "Letter to the Editor Regarding 'Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis'"Matthias Augustin, April W Armstrong, Naiem T Issa, et al.
Dermatology and Therapy|February 10, 2025
Interleukin-4 and Atopic Dermatitis: Why Does it Matter? A Narrative ReviewTiago Torres, Pedro Mendes-Bastos, Maria J Cruz, et al.
Journal of the American Academy of Dermatology|March 18, 2026
Reply to Woodie, et al., "Elevated risk of active tuberculosis with interleukin (IL)-17, IL-23, IL-12/23, Janus kinase inhibitors, cyclosporine, and tumor necrosis factor-α inhibitors compared with the general population: A population-based analysis using TriNetX."Tiago Torres, Andrew Blauvelt, Bruce Strober, et al.
Acta Medica Portuguesa|March 26, 2020
[Management of Psoriasis by Family Physicians: Referral Algorithm and Shared Management with Dermatology]Tiago Torres, Martinha Henrique, Hugo Oliveira, et al.
Dermatology and Therapy|February 10, 2025
The APOLO Study: A Cross-Sectional Analysis of Disease Characteristics and Patient Burden in Moderate-to-Severe Atopic Dermatitis in PortugalBruno Duarte, Pedro Mendes-Bastos, Joana Antunes, et al.
JAAD International|October 16, 2024
Risk factors that limit use of oral JAK inhibitors in chronic hand eczema: Findings from the Danish Skin CohortYuki M F Andersen, Johan Sieborg, Lea Nymand, et al.
Aquatic Toxicology (Amsterdam, Netherlands)|April 10, 2015
Ecological modelling and toxicity data coupled to assess population recovery of marine amphipod Gammarus locusta: Application to disturbance by chronic exposure to anilineCarmen B de los Santos, Teresa Neuparth, Tiago Torres, et al.
Pageof 28

Showing results (191-200 of 274) with videos related to

Sort By:
Pageof 28
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|April 13, 2025
Real-World Evidence on the Effectiveness and Safety of Spesolimab in the Treatment of Generalized Pustular Psoriasis Flares: A Case SeriesMartim Luz, M Ribeiro, M Alpalhão, et al.
Colloids and Surfaces. B, Biointerfaces|August 6, 2017
Topical co-delivery of methotrexate and etanercept using lipid nanoparticles: A targeted approach for psoriasis managementMara Ferreira, Luísa Barreiros, Marcela A Segundo, et al.
Dermatology and Therapy|October 23, 2025
Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic DermatitisMatthias Augustin, April Armstrong, Naiem T Issa, et al.
Dermatology and Therapy|June 26, 2026
A Response to: "Letter to the Editor Regarding 'Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis'"Matthias Augustin, April W Armstrong, Naiem T Issa, et al.
Dermatology and Therapy|February 10, 2025
Interleukin-4 and Atopic Dermatitis: Why Does it Matter? A Narrative ReviewTiago Torres, Pedro Mendes-Bastos, Maria J Cruz, et al.
Journal of the American Academy of Dermatology|March 18, 2026
Reply to Woodie, et al., "Elevated risk of active tuberculosis with interleukin (IL)-17, IL-23, IL-12/23, Janus kinase inhibitors, cyclosporine, and tumor necrosis factor-α inhibitors compared with the general population: A population-based analysis using TriNetX."Tiago Torres, Andrew Blauvelt, Bruce Strober, et al.
Acta Medica Portuguesa|March 26, 2020
[Management of Psoriasis by Family Physicians: Referral Algorithm and Shared Management with Dermatology]Tiago Torres, Martinha Henrique, Hugo Oliveira, et al.
Dermatology and Therapy|February 10, 2025
The APOLO Study: A Cross-Sectional Analysis of Disease Characteristics and Patient Burden in Moderate-to-Severe Atopic Dermatitis in PortugalBruno Duarte, Pedro Mendes-Bastos, Joana Antunes, et al.
JAAD International|October 16, 2024
Risk factors that limit use of oral JAK inhibitors in chronic hand eczema: Findings from the Danish Skin CohortYuki M F Andersen, Johan Sieborg, Lea Nymand, et al.
Aquatic Toxicology (Amsterdam, Netherlands)|April 10, 2015
Ecological modelling and toxicity data coupled to assess population recovery of marine amphipod Gammarus locusta: Application to disturbance by chronic exposure to anilineCarmen B de los Santos, Teresa Neuparth, Tiago Torres, et al.
Pageof 28